Protocadherins are a subfamily of the cadherin superfamily, but little is known about their functions. We identified a homozygous loss of protocadherin (PCDH) 17 in the course of a program to screen a panel of esophageal squamous cell carcinoma (ESCC) cell lines for genomic copy number aberrations. PCDH17 messenger RNA was expressed in normal esophageal tissue but not in the majority of ESCC cell lines without a homozygous deletion of this gene and restored in gene-silenced ESCC cells after treatment with 5-aza-2#-deoxycytidine. The DNA methylation status of the PCDH17 CpG island correlated inversely with the PCDH17 expression, and a putative methylation target region showed promoter activity. The methylation of the PCDH17 promoter was also associated with the silencing of gene expression in primary ESCC partly. Among primary ESCC cases, the silencing of PCDH17 protein expression was associated with a poorer differentiation status of ESCC cells and possibly with prognosis in a subset of this tumour. Restoration of PCDH17 expression in ESCC cells reduced cell proliferation and migration/invasion. These results suggest that silencing of PCDH17 expression through hypermethylation of the promoter or other mechanisms leads to loss of its tumour-suppressive activity, which may be a factor in the carcinogenesis of a subgroup of ESCCs.
Protocadherins are a subfamily of the cadherin superfamily, but little is known about their functions. We identified a homozygous loss of protocadherin (PCDH) 17 in the course of a program to screen a panel of esophageal squamous cell carcinoma (ESCC) cell lines for genomic copy number aberrations. PCDH17 messenger RNA was expressed in normal esophageal tissue but not in the majority of ESCC cell lines without a homozygous deletion of this gene and restored in gene-silenced ESCC cells after treatment with 5-aza-2#-deoxycytidine. The DNA methylation status of the PCDH17 CpG island correlated inversely with the PCDH17 expression, and a putative methylation target region showed promoter activity. The methylation of the PCDH17 promoter was also associated with the silencing of gene expression in primary ESCC partly. Among primary ESCC cases, the silencing of PCDH17 protein expression was associated with a poorer differentiation status of ESCC cells and possibly with prognosis in a subset of this tumour. Restoration of PCDH17 expression in ESCC cells reduced cell proliferation and migration/invasion. These results suggest that silencing of PCDH17 expression through hypermethylation of the promoter or other mechanisms leads to loss of its tumour-suppressive activity, which may be a factor in the carcinogenesis of a subgroup of ESCCs.
Introduction
Esophageal carcinoma is the sixth most frequent cause of cancerrelated death worldwide (1) , and esophageal squamous cell carcinoma (ESCC) accounts for $90% of esophageal carcinomas diagnosed in Asian countries. Although various genetic events that contribute to the development of ESCC have been investigated in the context of mutations or disruptions in DNA sequence that either activate oncogenes or lead to loss of function of tumour suppressor genes (TSGs), the ge-netic changes identified in ESCC cannot fully account for the pathogenesis of this disease. To identify novel TSGs, homozygously deleted regions within the cancer cell genome are probably to serve as a useful landmark (2) (3) (4) (5) , although biallelic loss is a rare event and other factors, such as point mutations and epigenetic abnormalities (6) , may predominantly contribute to the functional inactivation of TSGs. Therefore, high resolution mapping of homozygous deletions in cancer cells would be of considerable help in the rapid identification of TSGs regardless of the predominant cause of inactivation.
Previously, we applied an in-house bacterial artificial chromosome array containing 800 bacterial artificial chromosome clones (7) to an array-based comparative genomic hybridization (aCGH) analysis of a panel of ESCC cell lines and successfully identified 'low-density lipoprotein receptor-related protein 1B' as a potential TSG for ESCC frequently inactivated by either homozygous deletion or DNA methylation from homozygous loss detected in one cell line (8) . Since the homozygous loss is usually small, more TSGs involved in esophageal carcinogenesis are expected to be identified through a higher resolution search for copy number alterations (9) .
In the course of a program to screen a panel of ESCC cell lines for copy number aberrations by aCGH using high-density oligonucleotide arrays, we have identified a homozygous loss of the protocadherin (PCDH) 17 gene (13q21.2), the expression of which was absent in the majority of ESCC cell lines without homozygous loss, although it was present in normal esophageal tissue. Several PCDHs, a major subfamily of the cadherin superfamily (10) , including PCDH8, PCDH10 and PCDH20, are frequently silenced in carcinomas of the breast, nasopharynx and lung, respectively, due to deletion, mutation or promoter methylation and inhibit cell migration or anchoragedependent or -independent proliferation (11) (12) (13) (14) , suggesting that they can function as TSGs. Since PCDH17 is in the same subgroup, the Pcdhd2 subgroup, as PCDH8 and PCDH10, we focused on it as a candidate for an esophageal TSG, although the biological role and clinical significance of PCDH17 in ESCC remain unclear.
Materials and methods
Cell culture and primary tissue samples A total of 43 ESCC cell lines were used, of which 31 belonged to the KYSE series established from surgically resected tumours (15) and 12 were TE-series lines provided by the Cell Resource Center for Biomedical Research, Institute of Development, Aging and Cancer, Tohoku University, Japan. To analyse the restoration of PCDH17, cells were treated with or without 5 lmol/l of 5-aza-2#-deoxycytidine for 5 days and/or 300 nmol/l of trichostatin A for the last 12 h.
Primary tumour samples and corresponding non-cancerous esophageal mucosa obtained during surgery from 13 ESCC patients undergoing tumour resection at the Tokyo Medical and Dental University Hospital (Tokyo, Japan) were frozen immediately in liquid nitrogen and stored at À80°C until required. A total of 145 ESCC tumour samples including the 13 samples described above had been obtained from ESCC patients treated at the Tokyo Medical and Dental University Hospital between January 2000 and March 2006 and embedded in paraffin after 24 h of formalin fixation. Relevant clinical and survival data were available for all patients. Written consent was always obtained in the formal style and after approval by the local ethics committee. None of the patients in either group had received chemotherapy or radiation before surgery. Disease stage was defined in accordance with the tumor-lymph node-metastases classification (16) and the Japanese Classification of Esophageal Cancer (17) . Patients treated by non-curative resection or who died of other diseases were not included in this study. The median follow-up period for the surviving patients was 53 (ranging from 1 to 110) months.
Genomic polymerase chain reaction
Homozygous deletions were confirmed by genomic polymerase chain reaction (PCR). Mutations within the coding region of PCDH17 were analysed by means of exon amplification and direct sequencing. Any base changes detected in samples were confirmed by sequencing each product in both directions. Primers were designed for genomic sequences around each exon (supplementary Table S1 is available at Carcinogenesis Online).
Quantitative real-time reverse transcription-PCR Levels of messenger RNA (mRNA) expression were measured using a quantitative real-time fluorescence detection method (ABI PRISM 7500 sequence detection System; Applied Biosystems, Foster City, CA) with TaqManÒ Gene Expression Assays (Applied Biosystems) according to the manufacturer's instruction. Gene expression values are expressed as ratios between the PCDH17 gene (Hs00205457_m1; Applied Biosystems) and an internal reference gene (Hs99999903_m1 for beta-actin, ACTB; Applied Biosystems) that provides a normalization factor for the amount of RNA and subsequently normalized with the value in the controls (relative expression level). Total RNA derived from normal human oesophagus was purchased from Ambion (Austin, TX). Each assay was performed in duplicate for each sample.
Combined bisulfite restriction analysis and bisulfite genomic sequencing
Genomic DNA was treated with sodium bisulfite and subjected to PCR using primers designed to amplify regions of interest (supplementary Table S2 is available at Carcinogenesis Online). For the combined bisulfite restriction analysis (COBRA), products were digested with BstUI or TaqI and electrophoresed (18) . After the gels were stained with ethidium bromide, the intensities of methylated alleles (as a percentage) were calculated by densitometry using MultiGauge 2.0 (Fuji Film, Tokyo, Japan). A methylation density cut-off point of 20% was considered significant (8) . For the bisulfite genomic sequencing (BGS) analysis, the PCR products were subcloned and then sequenced.
Promoter reporter assay
Genomic DNA fragments of interest were obtained by PCR and ligated into the vector pGL3-Basic (Promega, Madison, WI). An equal amount of each construct or an empty pGL3-Basic vector was introduced into cells along with an internal control vector (pRL-hTK, Promega) using FuGENE6 (Roche Diagnostics, Tokyo, Japan). Firefly luciferase and Renilla luciferase activities were measured 36 h after transfection using the Dual-Luciferase Reporter Assay System (Promega), and relative luciferase activity was calculated and normalized versus Renilla luciferase activity.
Western blot analysis
Anti-PCDH17 rabbit polyclonal antibody was raised against a 15 amino acid peptide from human PCDH17 (DHPNRDLGRESVDAE; Operon Biotechnology, Tokyo, Japan) and purified through an affinity column. The anti-Myc-tag antibody was obtained from Cell Signaling Technology (Beverly, MA), the anti-FLAG-tag and anti-b-actin antibodies from Sigma (St Louis, MO) and the anti-p21, anti-p27 and anti-CCND1 antibodies from BD Biosciences (San Jose, CA), Santa Cruz Biotechnology (Santa Cruz, CA) and Cell Signaling Technology), respectively. For knocking down endogenous PCDH17 expression, each of the small interfering RNA (siRNAs) targeting PCDH17 (Stealth RNAi TM siRNA #HSS17838383, #HSS17838384 and #HSS17838385; Invitrogen, Carlsbad, CA) or a negative control (Negative universal control Med, Invitrogen) was transfected into cells (10 nmol/l) using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's instructions. Cell lysate was analysed by western blotting as described elsewhere (19) .
Immunohistochemistry
Indirect immunohistochemistry was performed with formalin-fixed paraffinembedded tissue sections. Antigens were retrieved by microwave pretreatment in citrate buffer (pH 9.0; Nichirei, Tokyo, Japan). After blocking in 2% normal swine serum, the slides were incubated with an anti-PCDH17 antibody (1:3000) overnight and then antigen-antibody reactions were visualized with the avidin-biotin complex kit (R.T.U. Vectastain Elite ABC Reagent; Vector Laboratories, Burlingame, CA) with diaminobenzidine tetrahydrochloride and hydrogen peroxide. The slides were counterstained with Mayer's hematoxylin.
Formalin-fixed PCDH17 expression construct-and empty vector-transfected KYSE170 cells as described below were used as positive and negative controls, respectively. The specificity of the antibody was verified by western blotting and absorption testing using synthesized peptides (supplementary Figure S1 is available at Carcinogenesis Online). All sections were analysed under a light microscope by two pathologists blinded to clinical characteristics and outcomes. Twenty representative fields per slide were examined at a magnification of Â200. The tumour regions positive for PCDH17 were defined as those containing tumour cells with cytomembrane staining of high intensity surrounded by stromal cells (see supplementary Figure S1 , available at Carcino-genesis Online). Patients positive for PCDH17 were defined as those with at least 20 positive regions in 20 images.
Immunofluorescence cytochemistry
Plasmids expressing C-terminally Myc-tagged PCDH17 (pCMV-3Tag4A-PCDH17) and C-terminally FLAG-tagged PCDH17 linked with green fluorescent protein by an internal ribosomal entry site (pIRES-hGFPII-PCDH17) were obtained by cloning the reverse transcription-PCR products of the full coding sequence of PCDH17 in-frame along with the 3XMyc-and 3XFLAGepitope into the eukaryotic expression vector pCMV-3Tag4A (Stratagene, La Jolla, CA) and pIRES-hGFPII (Stratagene), respectively. Cells transfected with each construct or the empty vector were fixed in methanol, incubated with the anti-MYC or anti-FLAG-tag antibody (1:100) and/or the anti-PCDH17 antibody (1:100) followed by incubation with a 1:100 dilution of Alexafluor 488 or 594 conjugated anti-mouse or anti-rabbit antibody (Invitrogen) and counterstained with 4#,6-diamidino-2-phenylindole dihydrochloride (0.15 lg/ml).
Growth assay
For colony formation assays, pCMV-3Tag4A-PCDH17 or the empty vector (pCMV-3Tag4A-mock) was introduced into cells using Lipofectamine 2000 (Invitrogen). The expression of PCDH17 protein was confirmed 48 h after transfection by western blotting and immunofluorescence cytochemistry. For colony formation assays, cells were fixed with 70% ethanol and stained with crystal violet after 10 days of incubation in six-well plates with appropriate concentrations of G418.
Stable PCDH17 transfectants and control counterparts were obtained by introducing pIRES-hGFPII-PCDH17 or pIRES-hGFPII-empty into KYSE170 and KYSE200 cells lacking PCDH17 expression. For measurements of cell growth, 1 Â 10 4 cells were seeded in 24-well plates. The numbers of viable cells were assessed by the water-soluble tetrazolium salt assay at 24-72 h after seeding. The cell cycle was evaluated by a fluorescence-activated cell sorting as described elsewhere (20) .
Effect of knocking down endogenous PCDH17 expression on cell growth were also assessed by water-soluble tetrazolium assay after introducing each of the siRNAs targeting PCDH17 (Stealth RNAi TM siRNA, Invitrogen) or a negative control (Negative universal control Med, Invitrogen).
Scratch wound assay
Stably transfected ESCC cells were cultured in six-well plates until confluent. The cell layers were carefully wounded using a sterile 20 ll tip, washed twice with fresh medium and cultured for 24 h. Images of the wound monolayers were acquired on a phase contrast microscope linked to a charge coupled device camera, and the wound area was measured using CT-AS software (Nikon, Tokyo, Japan) counting the number of pixels after the photographs had been converted to TIFF images.
Transwell migration and invasion assays
Transwell migration and invasion assays were carried out in 24-well modified Boyden chambers (transwell-chamber, BD Transduction, Franklin Lakes, NJ) as described elsewhere (21) . The upper surface of 6.4 mm diameter filters with 8 lm pores was precoated with (invasion assay) or without (migration assay) Matrigel (BD Transduction). Stable transfectants (2 Â 10 4 cells per well) were transferred into the upper chamber. Following 48 h of incubation, the migrated or invasive cells on the lower surface of filters were fixed and stained with the Diff-Quik stain (Sysmex, Kobe, Japan), and stained cell nuclei were counted directly in triplicate. We assessed invasive potential by calculating an invasion index, which is the ratio of the percentage invasion through the Matrigel-coated filters relative to the migration through the uncoated filters of test cells over that in the control counterparts.
Statistical analysis
Differences between subgroups were tested with the Student's t-test. Correlations between PCDH17 expression in primary tumours and the clinicopathologic variables pertaining to the corresponding patients were analysed for statistical significance with the v 2 or Fisher's exact tests. For the analysis of survival, Kaplan-Meier survival curves were constructed for groups based on univariate predictors and differences between the groups were tested with the log-rank test. Differences were assessed with a two-sided test and considered significant at a P ,0.05 level.
Results
The oligonucleotide aCGH identified a homozygous loss of PCDH17 in ESCC cell lines As expected, various small high-level amplifications (log 2 ratio . 2.0) and homozygous deletions (log 2 ratio , À2.0), not previously identified with conventional CGH or bacterial artificial chromosome aCGH (8, 22) , were detected in 43 ESCC cell lines with the highdensity oligonucleotide array. Among these newly identified regions, the homozygous loss at 13q21.2, which is within the PCDH17 gene and located close to two possible TSGs reported previously, PCDH8 (13) and PCDH20 (11), was detected in the KYSE890 and KYSE1170 cell lines ( Figure 1a and data not shown). To confirm the homozygous loss of PCDH17 in those lines and determine whether this segment might be homozygously lost in other ESCC lines, we performed genomic PCR using primers designed for exons 1-4 of this gene. We detected a homozygous loss of a part of PCDH17, between exons 1 and 3, only in KYSE890 and KYSE1170 cells ( Figure 1b ). Since no loss of PCDH17 had ever been documented in cancers including ESCC before, we examined whether this gene is a candidate TSG involved in tumourigenesis in the oesophagus.
Frequent transcriptional silencing of PCDH17 in ESCC cell lines Next, we examined the mRNA expression of PCDH17 by means of the real-time quantitative reverse transcription-PCR in all ESCC cell lines and normal oesophagus. Compared with the normal oesophagus, the KYSE890 and KYSE1170 cells as well as most of the other ESCC lines without homozygous loss at 13q21.2 (39 of 41, 95.1%) lacked expression of PCDH17 mRNA ( Figure 1c ). Two ESCC cell lines (KYSE110 and KYSE140) and normal oesophagus did express PCDH17 mRNA, suggesting the loss of expression in some tumours to result from mechanisms other than genomic deletion, including epigenetic events. Eleven of 41 lines showed a hemizygous loss pattern around PCDH17 on aCGH analysis, and 10 of them failed to express this gene ( Figure 1c and data not shown). We first screened nucleotide substitutions within the protein-coding sequence of PCDH17 in a panel of 41 ESCC cell lines without homozygous deletion of this gene and 50 ESCC primary tumours (Table I) . Only one heterozygous and one homozygous nucleotide substitution leading to a Gly / Arg change at codon 56 and a Glu / Lys change at codon 776, respectively, were identified in KYSE70 and KYSE110/ KYSE200 cells, respectively. Two silent heterozygous nucleotide substitutions detected in primary ESCC tumours were also observed in paired non-cancerous esophageal tissues (Table I ), suggesting those alteration to be single-nucleotide polymorphisms. No homozygous deletion was observed in 50 primary ESCC tumours. Although the observed alterations with amino acid changes have not been reported in the single-nucleotide polymorphism databases (http://www.ncbi .nlm.nih.gov/SNP/ and http://snp.ims.u-tokyo.ac.jp/), nucleotide substitutions within the protein-coding sequence may not play a major role in the silencing of PCDH17.
As recognized recently, candidate TSGs are more frequently inactivated through epigenetic inactivation (promoter methylation), or a combination of genetic (mutations of one allele) and epigenetic (methylation of another allele) inactivations, than biallelic genetic inactivation alone (6) . Since the CpGPLOT program (http://www .ebi.ac.uk/emboss/cpgplot/) identified a CpG-rich region containing a CpG island around the transcriptional start site (TSS) of PCDH17, we investigated whether DNA demethylation could restore the expression of PCDH17 mRNA. Treatment of ESCC cell lines lacking PCDH17 expression with 5-aza-2#-deoxycytidine restored PCDH17 mRNA expression ( Figure 1d ), although we observed an enhancement of PCDH17 mRNA expression by 5-aza-2#-deoxycytidine given along with trichostatin A in some lines, suggesting that histone deacetylation does play some role in the transcriptional silencing of PCDH17 among methylated ESCC cells.
Methylation of the PCDH17 CpG island in ESCC cell lines
To show the potential role of methylation around the CpG island in the silencing of PCDH17, we screened the methylation status around the PCDH17 CpG island (Figure 2a ) in ESCC lines by means of the COBRA and BGS. Since a preliminary screening using the COBRA demonstrated that most of the CpG island was highly methylated in ESCC cell lines regardless of expression status of PCDH17 (Figure 2b and supplementary Figure S2 is available at Carcinogenesis Online), we excluded those regions from further analysis and focused on the region around TSS (regions 1-3 in Figure 2a ). CpG sites around PCDH17-TSS tended to be extensively methylated in the nonexpressing cell lines, whereas PCDH17-expressing ESCC lines were almost unmethylated or partially methylated (Figure 2b and c) . Because part of the CpG-rich region around the PCDH17-TSS seems to be a target for methylation and closely related to transcriptional silencing of the gene, we tested this region for promoter activity using two fragments encompassing or within this region (978 and 171 bp; fragments 1 and 2, respectively, in Figure 2a ) in ESCC cells. Regardless of the expression status of PCDH17 mRNA, a remarkable increase in transcriptional activity was a feature of constructs containing fragment 1 (Figure 2d ), suggesting that the region around specific CpG sites exhibiting promoter activity is a potential target for DNA methylation for silencing of PCDH17.
Methylation of the PCDH17 promoter region in primary ESCC tumours
To determine the extent to which aberrant methylation of PCDH17 might be also involved in silencing of the gene's expression in primary ESCCs, we examined the methylation status of this gene in 13 frozen sections of primary ESCCs with corresponding non-cancerous esophageal tissues by the COBRA of regions 1 and 2 (Figures 2a and 3a) . Aberrant methylation of PCDH17 was detected in 9 of 13 primary ESCC tissues (69.2%) predominantly in region 2 and was also detected in the corresponding non-cancerous esophageal tissues in two of those nine samples (22.2%), suggesting the aberrant methylation of the PCDH17 promoter region to occur early in esophageal carcinogenesis. We performed BGS of regions 1 and 2 in individual alleles from representative primary ESCC tumours with corresponding noncancerous tissues (Figure 3b ) and confirmed aberrant methylation in methylation-positive ESCC tumours but not in methylation-negative non-cancerous esophageal tissues in the COBRA. These findings indicate that the PCDH17 promoter's methylation was not a simple artifact arising during the passage of cell lines in vitro.
To compare PCDH17 methylation status with expression status, we carried out quantitative real-time reverse transcription-PCR and immunohistochemistry in primary tumour samples and corresponding non-cancerous tissues, although non-cancerous tissue samples were unavailable within paraffin-embedded tissues in some of the 13 cases. Decreased PCDH17 mRNA expression in tumours compared with paired non-cancerous tissues was observed in four of seven cases (57.1%) with tumour-specific hypermethylation and in two of five cases (40%) without tumour-specific hypermethylation (Figure 3c ), although methylation status and mRNA expression status did not match in 5 of 13 cases. In order to determine the protein expression status of PCDH17 in primary ESCC tumours and non-cancerous esophageal mucosa, we performed an immunohistochemical analysis using a PCDH17-specific antibody (Figure 3d ; supplementary Figure S1 is available at Carcinogenesis Online). In non-tumourous esophageal mucosa, PCDH17 immunoreactivity was predominantly observed on membranes of epithelial cells in prickle cell layers as a dotted pattern. PCDH17 immunostaining was observed in some mesenchymal cells, e.g. endothelial cells. Immunohistochemical staining using representative cases of ESCC tumours with DNA methylation and neighbouring non-cancerous tissues demonstrated that PCDH17 protein expression was detected in normal epithelial cells but not in tumour cells (Figure 3d ). Since silencing of PCDH17 protein expression in tumour tissues was correlated with tumour-specific methylation (P 5 0.476, Fisher's exact test) even in nine paired analysis sets, those results suggested that methylation within the promoter region of PCDH17 occurs in primary ESCC and partly contributes to the silencing of expression.
Association between clinicopathologic characteristics and the PCDH17 protein expression
To verify the downregulation of PCDH17 expression in primary ESCCs and to determine its clinicopathologic significance, we further performed an immunohistochemical analysis of PCDH17 protein in 145 primary tumour tissues. Table II summarizes relationships between the expression status of PCDH17 protein and clinicopathological features. Among the 145 ESCCs, 18 (12.4%) showed immunoreactivity to PCDH17 (positive in Table II ; supplementary Figure S1 is available at Carcinogenesis Online), whereas 127 (87.6%) did not (negative in Table II and Figure 3d ). Negative PCDH17 expression was more frequent in male cases (P 5 0.015, v 2 test) and in poorly differentiated tumours than in well/moderately differentiated tumours (histopathological grading, P 5 0.032, Fisher's exact test) and tended to be more frequent in pN1 than pN0 tumours (P 5 0.086, v 2 test). However, the PCDH17 protein expression in each tumour was not associated with other characteristics. Univariate analyses of overall survival with log-rank tests failed to demonstrate a significant association between PCDH17 expression status and overall survival of patients (supplementary Figure S3 is available at Carcinogenesis Online). However, no deaths occurred in the PCDH17-positive group of patients (n 5 10) with pN0 ESCC tumours during the study period, whereas 9 of 44 patients (20.5%) in the negative group died (Figure 3e ). No clinicopathological difference was observed between the PCDH17-positive and -negative groups (supplementary Table S3 is available at Carcinogenesis Online) in cases with pN0 ESCC tumours, suggesting negative PCDH17 immunoreactivity to be useful for predicting the selection of therapeutic approaches in this less advanced group.
Suppression of cell proliferation and migration after restoration of PCDH17 expression
To investigate whether restoration of PCDH17 expression would suppress proliferation of ESCC cells lacking expression of the gene, we first performed colony formation assays using transiently PCDH17transfected cells (Figure 4a ). Ten days after transfection and subse-quent selection of drug-resistant colonies, the numbers of large colonies produced by PCDH17-transfected KYSE170 and KYSE200 cells decreased compared with those of empty vector-transfected counterparts. Expectedly, immunofluorescence staining demonstrated that ectopically expressed PCDH17 protein was mainly located at plasma membranes (supplementary Figure S4 is available at Carcinogenesis Online). A cell proliferation assay was also performed for stably transfected KYSE170 and KYSE200 cells (Figure 4b ). Cells stably expressing FLAG-tagged PCDH17 (Figure 4c ) grew slightly but significantly slower than the empty vector-transfected cells. In fluorescence-activated cell sorting analysis, an accumulation of cells in G 0 -G 1 phase and a decrease in S and G 2 -M phase cells but no increase in sub-G 1 phase cells was observed among PCDH17transfected KYSE170 and KYSE200 cells compared with mocktransfected counterparts (Figure 4c ), suggesting that PCDH17 contributes to the arrest of ESCC cells at the G 1 -S checkpoint without inducing apoptosis. In PCDH17-transfected cells, an upward trend in p21 and p27 protein expression and a downward trend in CCND1 protein expression were observed compared with their control counterparts ( Figure 4c ). Next, the effect of restoring PCDH17 expression on ESCC cell motility was assessed with a scratch wound assay. Stably PCDH17-expressing KYSE170 cells spread along the wound edges significantly slower than empty vector-transfected counterparts (Figure 4d) , indicating that PCDH17 also inhibits tumour cell migration. Furthermore, a Matrigel invasion assay was performed to examine the invasive potential of KYSE170 cells transfected with PCDH17. The number of cells that migrated through the uncoated (migration assay) or Matrigel-coated (invasion assay) membrane into the lower chamber and the invasion index, the relative number of cells that migrated through the uncoated membrane compared with those that migrated through the Matrigel-coated membrane (Figure 4d ), were significantly lower in the stably PCDH17-expressing cells than in control cells, suggesting that PCDH17 also inhibits the invasive potential of ESCC cells.
Discussion
The introduction of higher density aCGH and the vast amounts of mapping data that have recently become available through the human genome effort have greatly facilitated the analysis of tumour-related amplified or deleted chromosomal regions. Since cell lines and xenografts are superior to primary tumour samples for the identification of homozygous deletions and many of the most important TSGs have been discovered through the use of cell lines and xenografts (23), we applied high-resolution oligonucleotide arrays to ESCC cell lines, an approach that provides high sensitivity and specificity in detecting cryptic homozygous losses, to identify novel TSGs.
Homozygous loss of PCDH17, which is located close to PCDH20, another member of the protocadherin superfamily homozygously deleted in a non-small-cell lung cancer cell line at 13q21 (11) , was detected in two ESCC cell lines. Notably, within the non-clustered d2 subgroup (PCDH8, 10, 17, 18 and 19) of the .70 members of the protocadherin family (10), PCDH8 and PCDH10 have been reported as candidate TSGs (12) (13) (14) . However, a role for PCDH17 within the same subgroup in carcinogenesis has never been reported, prompting us to focus on its gene.
The frequently reduced expression of PCDH17 is linked closely to hypermethylation of the CpG-rich region having promoter activity in ESCC cell lines, indicating that promoter methylation is one of the mechanisms for PCDH17's inactivation in ESCC. There are partially methylated alleles in several cell lines with no expression and unmethylated alleles in many primary ESCC tumours, indicating that other factors regulating transcription such as the modification of histones, a lack of transcriptional activators or the presence of transcriptional repressors may contribute to the gene silencing especially in primary tumours. Although we detected several non-synonymous nucleic acid alterations in coding exons of PCDH17 in ESCC cell lines, it remains unclear whether they contribute to the silencing/inactivation of this gene because of a lack of evidence indicating those alterations to be somatic mutations in ESCC cells.
Loss of expression or functional inactivation, caused by mutations or promoter methylation of members of the cadherin superfamily, e.g. CDH1, CDH13, CDH11, PCDH-LKC, PCDH-c-A11, PCDH8 and PCD10, has been shown in a number of different cancer entities (12) (13) (14) (24) (25) (26) (27) (28) (29) (30) , resulting in tumour cell invasion and metastasis (12, 14, 24, 31) . Those results are complementary to ours and suggest that epigenetic inactivation of members of the cadherin superfamily including protocadherins in neoplasms could be widespread and more genes in this family may be targets for inactivation during tumourigenesis, although protein structure, expression patterns in various tissues and physiologic function differ among members (10) . Notably, PCDH8, PCDH17, PCDH20 and PCDH9 around 13q21.1 locate contiguously, even though non-clustered protocadherin members, and PCDH8 and PCDH20 are reported to be candidate TSGs acting through genetic or epigenetic inactivation (11, 13) , suggesting that the neighbouring protocadherins around 13q21.1 are broadly involved in tumour suppression in a range of tumour types independently or synergistically through common or unique mechanisms.
Our promoter assay demonstrated that fragment containing a methylated region differing between PCDH17-expressing and nonexpressing ESCC cell lines and located upstream (5#) of exon 1 of PCDH17 showed a remarkable promoter activity. Therefore, sequences within the 5# part of TSS at least seem to be the target for the methylation-induced silencing of PCDH17. In primary cases of ESCC, tumour samples were more frequently methylated especially in the promoter region of PCDH17 compared with paired non-tumourous samples, suggesting that aberrant methylation of the PCDH17 promoter region is not a cell line-specific event. In some cases, higher expression of PCDH17 mRNA was observed in methylated tumours than in paired non-tumourous samples without methylation, probably due to the expression of PCDH17 mRNA from the unmethylated portion of tumour cells as well as non-cancerous normal tissue components, such as epithelial cells in the prickle cell layer and endothelial cells in submucosa, contaminating the tumour samples.
Immunohistochemical analysis in 145 primary ESCCs revealed frequent silencing of PCDH17 protein expression in tumour cells. (b) A vector that carries two transgenes, green fluorescent protein and a C-terminally FLAG-tagged PCDH17 linked by an internal ribosomal entry site (pIRES-hGFPII-PCDH17) or empty vector (pIRES-hGFPII-mock) as a control was stably introduced into KYSE170 or KYSE200 cells lacking expression of the PCDH17 gene with selection using G418. Immunofluorescence cytochemistry using anti-FLAG antibody demonstrated almost all KYSE170 or KYSE200 cells stably transfected with pIRES-hGFPII-PCDH17 to express FLAG-tagged PCDH17 (upper). A cell growth assay of stable transfectants using water-soluble tetrazolium salt after plating into 24-well plates (1 Â 10 5 cells per well) revealed the proliferative activity of PCDH17-transfected cells to be less than that of the control counterparts. Mean ± SD for three separate experiments, each done in triplicate. Ã P , 0.05 versus mock-transfected control at each time-point (Student's t-test). (c) Representative results of cell cycle analysis and the protein expression of cell cycle-related molecules, such as p21, p27 and CCND1, assessed by fluorescenceactivated cell sorting (left) and western blotting (right), respectively, in stably PCDH17-transfected KYSE170 or KYSE200 cells and their control counterparts. (d) Cell mobility was assessed by a scratch-wound assay (left) and a transwell migration assay (right), whereas cell invasion was assessed by a transwell invasion assay (right). (Left) Scratch-wound assay using stable transfectants shown in Figure 4c and quantification of the results were described in 'Materials and Methods'. Experiments were performed in triplicate. The scratch area at 0 h was arbitrarily assigned as 1.0. Ã P , 0.05 versus mock-transfected control at each time-point (Student's t-test). (Right) Transwell migration and invasion assays were carried out in 24-well modified Boyden chambers without and with Matrigel (BD Transduction), respectively. Cells (2 Â 10 4 cells per well) were transferred into the upper chamber, and the migrated or invasive cells on the lower surface of filters were fixed, stained and counted after 48 h of incubation. Experiments were performed in triplicate. We assessed invasive potential by calculating an invasion index, which is the ratio of the percentage invasion through the Matrigel-coated filters relative to the migration through the uncoated filters of test cells over that in the control counterparts. Columns, mean for three separate experiments, each done in triplicate; bars, SD. Ã P , 0.05 versus mock-transfected control at each time-point (Student's t-test).
Since the frequency of the silencing of PCDH17 protein expression in primary ESCC tumours was higher than that expected from the methylation and mRNA expression analysis, mechanisms other than DNA methylation, including posttranslational modification, may contribute to the downregulation of PCDH17 expression. Notably, a significant correlation existed between the expression of PCDH17 protein and histopathological grading and poorly differentiated tumours were negative for PCDH17 expression more frequently than were welldifferentiated tumours. In neighbouring non-neoplastic esophageal epithelia, PCDH17 protein was expressed in regions containing differentiated cells (prickle cell layer) but not in those containing actively dividing cells (basal cell layer). In our preliminary multi-tissue mRNA expression analysis using various human tissues, relatively higher expression of PCDH17 mRNA compared with normal oesophagus was observed in brain, lung, pancreas and heart, but similar or lower expression was observed in most of other tissues and tissues with squamous epithelial cells, such as cervix and skin, showed similar PCDH17 mRNA expression level, suggesting PCDH17 to play some role in normal squamous epithelia (supplementary Figure S6 is available at Carcinogenesis Online). Those findings suggest the expression of PCDH17 to depend on the status of cellular differentiation and the silenced expression of PCDH17 to play some role during the de-differentiation of esophageal neoplasms. Although no significant difference in overall survival was observed between cases with and without expression of PCDH17 protein in ESCC tumours, no deaths occurred in the PCDH17-positive group of patients with pN0 ESCC tumours during the study period, whereas 20.5% of patients in the negative group died. In addition, PCDH17 protein expression tended to be more frequently detected in pN0 ESCC tumours, suggesting PCDH17-immunopositivity to be one of the signs of a less malignant phenotype at least for some subgroups of ESCC. In a previous multicenter randomized controlled trial in Japan (JCOG9204) to determine whether postoperative adjuvant chemotherapy improves outcome in patients with ESCC undergoing radical surgery (32), risk reduction by postoperative chemotherapy was remarkably observed only in the subgroup with pN1. This result suggests that some high risk subgroups within pN0 cases, in which postoperative chemotherapy may be more desirable, should be detected by biomarkers for prediction of latent micrometastases and choosing the most favourable options for treatment of individual ESCC patients, especially pN0 cases. Therefore, postoperative chemotherapy may be required for patients negative for PCDH17 expression in the primary tumour in cases of pN0 ESCC. To test this hypothesis, it will be necessary to analyse cohorts consisting of more cases of ESCC because only a small proportion of cases show PCDH17 staining.
The tumour-suppressive function of PCDH17 in ESCC was investigated by re-expression of this gene in ESCC cell lines in vitro. Colony-formation assays using transiently PCDH17-transfected cells and growth assays using stably PCDH17-transfected cells or siRNAtreated cells (supplementary Figure S5 is available at Carcinogenesis Online) showed an anti-proliferative activity of the PCDH17 protein.
Stably PCDH17-transfected cells demonstrated cell cycle arrest at the G 1 -S checkpoint. In addition, we observed that re-expression of PCDH17 induces inhibition of cell migration and invasion. Different from classic cadherins, it is known that protocadherins are not just simple cell adhesion proteins involved in homophilic interactions and their heterophilic interactions with other molecules may be more important for their various physiologic functions (10, 33, 34) . Therefore, PCDH17 may have multiple tumour-suppressive functions potentially contributing to cell-cell adhesion, signal transduction and growth control, although the exact function of PCDH17 is poorly defined and no motif possibly associated with any specific function has been reported. In other protocadherins, various possible mechanisms for tumour suppression have been reported: PCDH10 inhibits cell proliferation and induces apoptosis with an induction of multiple genes including p21 (14) , and PCDH24 inhibits the expression of some downstream targets of b-catenin including cyclin D1 (35) . Therefore, it is possible that some of the molecular pathways for tumour suppression are common to protocadherins including PCDH17, although it remains unclear whether protocadherins directly or indirectly regulate those molecules related to the cell cycle and apoptosis. However, the tumour-suppressing activity of PCDH17 in vitro, together with its expression in normal esophageal epithelial cells, specifically at the prickle cell layer, and the correlation between the silenced PCDH17 expression in ESCC cells and poorer differentiation status, support the candidacy of this gene as a TSG for ESCC. Additional studies will be required to unravel the carcinogenic consequences of loss of PCDH17 function in human esophageal tissue.
Supplementary material
Supplementary Figures S1-S6 and Tables S1-S3 can be found at http://carcin.oxfordjournals.org/ 
